Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1989 1
1990 2
1991 2
1992 3
1993 1
1994 1
1995 2
1997 1
2002 4
2005 3
2009 3
2010 2
2011 1
2012 3
2013 1
2014 1
2015 1
2016 1
2017 3
2018 4
2019 4
2020 6
2021 7
2022 13
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Pathophysiology of Atypical Atrial Flutters.
Marazzato J, Marazzi R, Doni LA, Blasi F, Angeli F, Bagliani G, Leonelli FM, De Ponti R. Marazzato J, et al. Among authors: doni la. Card Electrophysiol Clin. 2022 Sep;14(3):411-420. doi: 10.1016/j.ccep.2022.03.002. Epub 2022 Aug 25. Card Electrophysiol Clin. 2022. PMID: 36153123 Review.
Arrhythmias Involving Variants of Accessory Pathways.
Marazzato J, Marazzi R, Doni LA, Angeli F, Bagliani G, Leonelli FM, De Ponti R. Marazzato J, et al. Among authors: doni la. Card Electrophysiol Clin. 2020 Dec;12(4):505-518. doi: 10.1016/j.ccep.2020.08.001. Epub 2020 Sep 26. Card Electrophysiol Clin. 2020. PMID: 33161999 Review.
Mapping and Ablation of Atypical Atrial Flutters.
Marazzato J, Marazzi R, Doni LA, Angeli F, Bagliani G, Leonelli FM, De Ponti R. Marazzato J, et al. Among authors: doni la. Card Electrophysiol Clin. 2022 Sep;14(3):471-481. doi: 10.1016/j.ccep.2022.03.003. Epub 2022 Aug 25. Card Electrophysiol Clin. 2022. PMID: 36153127 Review.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, De Giorgi U, Bimbatti D, Nolè F, Carrozza F, Buti S, Iacovelli R, Ciccarese C, Masini C, Baldessari C, Doni L, Cusmai A, Gernone A, Scagliarini S, Pignata S, de Braud F, Verzoni E. Procopio G, et al. Among authors: doni l. Tumori. 2023 Feb;109(1):129-137. doi: 10.1177/03008916221138881. Epub 2022 Nov 29. Tumori. 2023. PMID: 36447337 Free PMC article. Clinical Trial.
Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, Maruzzo M, Mosca A, Pisano C, Verzoni E, Zucali PA. Rossi E, et al. Among authors: doni l. Curr Oncol Rep. 2021 Nov 8;23(12):147. doi: 10.1007/s11912-021-01140-9. Curr Oncol Rep. 2021. PMID: 34748099 Free PMC article. Review.
79 results